ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 695,78
0,83%
Dow Jones
39 308,00
-0,06%
DAX
18 450,48
0,38%
Brent Oil
87,27
0,41%
Bitcoin
57 854,74
-3,84%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Verona Pharma Plc (VRNA)

  7. Verona Pharma Plc (VRNA) Actualités

VRNA

Verona Pharma (VRNA)

Verona Pharma Plc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VRNA
DateHeureSourceTitreSymboleSociété
26/06/202422h57GlobeNewswire Inc.Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)NASDAQ:VRNAVerona Pharma Plc
10/05/202415h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRNAVerona Pharma Plc
10/05/202414h53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRNAVerona Pharma Plc
09/05/202413h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRNAVerona Pharma Plc
09/05/202413h15GlobeNewswire Inc.Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
09/05/202413h00GlobeNewswire Inc.Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSNASDAQ:VRNAVerona Pharma Plc
02/05/202408h00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024NASDAQ:VRNAVerona Pharma Plc
25/04/202408h00GlobeNewswire Inc.Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
08/03/202422h18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VRNAVerona Pharma Plc
08/03/202403h40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
04/03/202408h00GlobeNewswire Inc.Andrew Fisher Joins Verona Pharma as General CounselNASDAQ:VRNAVerona Pharma Plc
29/02/202415h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VRNAVerona Pharma Plc
29/02/202408h00GlobeNewswire Inc.Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
15/02/202408h00GlobeNewswire Inc.Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
06/02/202400h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
05/02/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRNAVerona Pharma Plc
01/02/202408h00GlobeNewswire Inc.Michael Austwick Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/01/202408h00GlobeNewswire Inc.Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRNAVerona Pharma Plc
02/01/202408h00GlobeNewswire Inc.Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalNASDAQ:VRNAVerona Pharma Plc
17/11/202308h00GlobeNewswire Inc.Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardNASDAQ:VRNAVerona Pharma Plc
08/11/202308h00GlobeNewswire Inc.Verona Pharma Announces November 2023 Investor Conference ParticipationNASDAQ:VRNAVerona Pharma Plc
02/11/202308h04GlobeNewswire Inc.Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
19/10/202308h00GlobeNewswire Inc.Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
06/10/202308h00GlobeNewswire Inc.Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023NASDAQ:VRNAVerona Pharma Plc
03/10/202308h00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023NASDAQ:VRNAVerona Pharma Plc
11/09/202308h00GlobeNewswire Inc.Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDNASDAQ:VRNAVerona Pharma Plc
06/09/202308h00GlobeNewswire Inc.Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023NASDAQ:VRNAVerona Pharma Plc
31/08/202308h00GlobeNewswire Inc.Christina Ackermann Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/08/202308h00GlobeNewswire Inc.Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
26/07/202308h00GlobeNewswire Inc.Verona Pharma to Present at 43rd Annual Canaccord Growth ConferenceNASDAQ:VRNAVerona Pharma Plc
 Showing the most relevant articles for your search:NASDAQ:VRNA

Dernières Valeurs Consultées

CRTO
FXSBTC
Frax Share
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés